Short term efficacy and toxicity of apatinib and docetaxel combined with cisplatin chemotherapy for advanced gastric cancer
10.3872/j.issn.1007-385X.2018.11.008
- VernacularTitle:阿帕替尼与多西他赛联合顺铂化疗对晚期胃癌的近期疗效及毒副反应
- Author:
GAO Shile
1
,
2
,
3
,
4
;
LU Donghui
1
,
2
,
3
,
4
;
LIU Meiqin
1
,
2
,
3
,
4
;
WANG Chong
1
,
2
,
3
,
4
;
WEI Lei
1
,
2
,
3
,
4
;
XU Peng
1
,
2
,
3
,
4
;
LIU Yan
1
,
2
,
3
,
4
;
TANG Zhengzhong
1
,
2
,
3
,
4
;
HU Zongtao
5
Author Information
1. Four Families of Tumor
2. One Families of Tumor
3. Five Families of tumor
4. The 901st Hospital of the PLA Joint Logistics Support Force [Primary the 105th Hospital of PLA]
5. Department of Radiotherapy, HeFei Cancer Hospital, ChineseAcademy of Sciences
- Publication Type:Journal Article
- Keywords:
apatinib；docetaxel；cisplatin；advanced gastric cancer；efficacy；toxic and side effects
- From:
Chinese Journal of Cancer Biotherapy
2018;25(11):1131-1134
- CountryChina
- Language:Chinese
-
Abstract:
Objective: : To observe the short-term efficacy and toxicity of apatinib monotherapy as well as docetaxel plus cisplatin in advanced gastric cancer. Method: : According to inclusion and exclusion criteria, 108 patients with advanced gastric cancer in the 105th Hospital of PLA were selected. According to random table grouping method, there were 54 cases in group A and 54 cases in group B. Patients in group A received continuous oral administration of apatinib alone, while group B received docetaxel plus cisplatin chemotherapy, with 3 weeks as a cycle and 4 cycles for a course. The efficacy and side effects were evaluated 3 months later. Results: : In groupA, there were 4 cases of CR, 25 cases of PR, 18 cases of SD and 7 cases of PD; the ORR was 53.7% and DCR was 87%. In group B, there were 2 cases of CR, 19 cases of PR, 21 cases of SD and 12 cases of PD; the ORR was 38.9% and DCR was 77.8%. The ORR and DCR in group A were significantly better than those in group B (P<0.05). The main adverse reactions were gastrointestinal reaction, myelosuppression, hypertension and hand-foot syndrome, all of which were grade 1 to 2; The incidence of bone marrow suppression and gastrointestinal reaction in group A was lower than that in group B (P<0.05), while the incidence of hand-foot syndrome and hypertension in group B was lower than that in group A (P<0.01). Conclusion： ：The short-term efficacy of targeted therapy of apatinib alone was better than that of docetaxel combined with cisplatin chemotherapy, and the toxicity and side effects of both regimens were controllable;Apatinib can be used as the primary regimen for the treatment of advanced gastric cancer.
- Full text:20181108.txt
